title: Severe esophageal bleeding in colorectal cancer due to antitumor therapy: A case report.
abstract: Colorectal cancer is the third most common type of cancer worldwide, with >1 million cases diagnosed each year. Gastrointestinal bleeding is a common complication of colorectal cancer and is usually associated with the erosion and hemorrhage of the primary tumor. However, in patients who undergo a radical hemicolectomy and do not develop local recurrence, gastrointestinal bleeding may be a result of medical treatments or comorbidities. Esophageal bleeding in such patients is rare. Here, a case of severe esophageal bleeding due to anti-angiogenesis therapy with bevacizumab, and chemotherapy with the FOLFIRI regimen (irinotecan, folinic acid and 5-fluorouracil) in a patient with colorectal cancer is reported, and the possible pathogenesis of this event is analyzed based on the existing literature, in order to provide a reference for such cases.
authors.affiliation: Department of Medical Oncology, Second Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
authors.forename: Hong
authors.initials: H
authors.lastname: Shen
authors.affiliation: Department of Medical Oncology, Second Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
authors.forename: Xian-Yun
authors.initials: XY
authors.lastname: Ye
authors.affiliation: Department of Medical Oncology, Second Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
authors.forename: Xiao-Fen
authors.initials: XF
authors.lastname: Li
authors.affiliation: Department of Gastroenterology, Second Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
authors.forename: Wen-Sheng
authors.initials: WS
authors.lastname: Pan
authors.affiliation: Department of Medical Oncology, Second Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
keywords: bevacizumab; chemotherapy; colorectal cancer; esophageal bleeding